Daisy Moreno

617 total citations
9 papers, 430 citations indexed

About

Daisy Moreno is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Daisy Moreno has authored 9 papers receiving a total of 430 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Hematology, 7 papers in Genetics and 2 papers in Molecular Biology. Recurrent topics in Daisy Moreno's work include Chronic Myeloid Leukemia Treatments (8 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Acute Myeloid Leukemia Research (3 papers). Daisy Moreno is often cited by papers focused on Chronic Myeloid Leukemia Treatments (8 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Acute Myeloid Leukemia Research (3 papers). Daisy Moreno collaborates with scholars based in United States, Switzerland and Australia. Daisy Moreno's co-authors include Jingrui Jiang, Elizabeth Hall–Meyers, Ellen Weisberg, Andrew L. Kung, James D. Griffin, Renee D. Wright, Arghya Ray, Laurie Catley, Paul W. Manley and Doriano Fabbro and has published in prestigious journals such as Blood, Gastroenterology and Molecular Cancer Therapeutics.

In The Last Decade

Daisy Moreno

8 papers receiving 423 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daisy Moreno United States	7	201	178	174	70	61	9	430
Elizabeth Hall–Meyers United States	5	159 0.8×	133 0.7×	97 0.6×	18 0.3×	49 0.8×	6	313
Zhifu Xiang United States	7	160 0.8×	176 1.0×	78 0.4×	15 0.2×	76 1.2×	22	355
Qurish K. Mohemmad United States	5	112 0.6×	304 1.7×	83 0.5×	42 0.6×	128 2.1×	5	481
Diana F. Sabath United States	5	327 1.6×	103 0.6×	141 0.8×	15 0.2×	51 0.8×	8	416
Nathalie Javidi‐Sharifi United States	7	158 0.8×	177 1.0×	71 0.4×	7 0.1×	44 0.7×	16	326
Lurdes Torres Portugal	11	72 0.4×	143 0.8×	32 0.2×	44 0.6×	101 1.7×	20	328
Stéphanie Guidez France	10	170 0.8×	126 0.7×	134 0.8×	172 2.5×	155 2.5×	45	387
Stefan Norin Sweden	9	78 0.4×	127 0.7×	216 1.2×	185 2.6×	131 2.1×	28	393
Елена Бибикова United States	9	153 0.8×	185 1.0×	326 1.9×	236 3.4×	69 1.1×	16	525
Ju-Hee Bang South Korea	13	51 0.3×	127 0.7×	53 0.3×	32 0.5×	247 4.0×	17	380

Countries citing papers authored by Daisy Moreno

Since Specialization

Citations

This map shows the geographic impact of Daisy Moreno's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daisy Moreno with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daisy Moreno more than expected).

Fields of papers citing papers by Daisy Moreno

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daisy Moreno. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daisy Moreno. The network helps show where Daisy Moreno may publish in the future.

Co-authorship network of co-authors of Daisy Moreno

This figure shows the co-authorship network connecting the top 25 collaborators of Daisy Moreno. A scholar is included among the top collaborators of Daisy Moreno based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daisy Moreno. Daisy Moreno is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Weisberg, Ellen, Laurie Catley, Renee D. Wright, et al.. (2016). Beneficial Effects of Combining Nilotinib and Imatinib in Preclinical Models of BCR/ABL+ Leukemias Nilotinib and Imatinib Against Bcr-Abl+ Leukemia.

Weisberg, Ellen, Hwan Geun Choi, Rosemary Barrett, et al.. (2010). Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors. Molecular Cancer Therapeutics. 9(9). 2468–2477. 12 indexed citations

Weisberg, Ellen, Johannes Roesel, Guido Bold, et al.. (2008). Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells. Blood. 112(13). 5161–5170. 28 indexed citations

Weisberg, Ellen, Lolita Banerji, Renee D. Wright, et al.. (2008). Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL– and mutant FLT3-expressing cells. Blood. 111(7). 3723–3734. 65 indexed citations

Weisberg, Ellen, Andrew L. Kung, Renee D. Wright, et al.. (2007). Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells. Molecular Cancer Therapeutics. 6(7). 1951–1961. 66 indexed citations

Leleu, Xavier, Xiaoying Jia, Judith Runnels, et al.. (2007). The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood. 110(13). 4417–4426. 104 indexed citations

Weisberg, Ellen, Renee D. Wright, Jingrui Jiang, et al.. (2006). Effects of PKC412, Nilotinib, and Imatinib Against GIST-Associated PDGFRA Mutants With Differential Imatinib Sensitivity. Gastroenterology. 131(6). 1734–1742. 75 indexed citations

Leleu, Xavier, Xiaoying Jia, Anne‐Sophie Moreau, et al.. (2006). Perifosine, an Oral Bioactive Novel Akt Inhibitor, Induces In Vitro and In Vivo Antitumor Activity in Waldenstrom Macroglobulinemia.. Blood. 108(11). 2488–2488. 1 indexed citations

Weisberg, Ellen, Laurie Catley, Renee D. Wright, et al.. (2006). Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood. 109(5). 2112–2120. 79 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact